Acumen Pharmaceuticals Inc (ABOS)
3.36
-0.20
(-5.62%)
USD |
NASDAQ |
May 10, 16:00
3.36
0.00 (0.00%)
After-Hours: 20:00
Acumen Pharmaceuticals Cash from Operations (TTM): -43.06M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -43.06M |
September 30, 2023 | -45.95M |
June 30, 2023 | -42.23M |
March 31, 2023 | -37.03M |
December 31, 2022 | -35.15M |
September 30, 2022 | -27.59M |
June 30, 2022 | -26.09M |
Date | Value |
---|---|
March 31, 2022 | -23.89M |
December 31, 2021 | -17.96M |
September 30, 2021 | -17.18M |
June 30, 2021 | -10.77M |
March 31, 2021 | -8.004M |
December 31, 2020 | -7.45M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-45.95M
Minimum
Sep 2023
-7.45M
Maximum
Dec 2020
-26.34M
Average
-26.09M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
Accuray Inc | 19.82M |
Kezar Life Sciences Inc | -81.64M |
Akoya Biosciences Inc | -50.90M |
NovaBay Pharmaceuticals Inc | -4.131M |
Palatin Technologies Inc | -26.54M |